TYSABRI 300 mg/15 mL koncentrat za rastvor za infuziju Bosnia ja Hertsegoviina - horvaadi - Agencija za lijekove i medicinska sredstva Bosne i Hercegovine (Агенција за лијекове и медицинска средства Босне и Херцеговине)

tysabri 300 mg/15 ml koncentrat za rastvor za infuziju

medis international d.o.o. sarajevo - natalizumab - koncentrat za rastvor za infuziju - 300 mg/15 ml - 1 bočica sa 15 ml koncetrata za rastvor za infuziju sadrži: 300 mg natalizumaba

AUBAGIO 14mg Film tableta Montenegro - horvaadi - CInMED-Institut za ljekove i medicinska sredstva Crne Gore

aubagio 14mg film tableta

dio stranog druŠtva "sanofi - aventis" - podgorica - teriflunomid - film tableta - 14mg

TYSABRI 150mg Rastvor za injekciju u napunjenom injekcionom špricu Montenegro - horvaadi - CInMED-Institut za ljekove i medicinska sredstva Crne Gore

tysabri 150mg rastvor za injekciju u napunjenom injekcionom špricu

druŠtvo za trgovinu na veliko farmaceutskim proizvodima "glosarij" d.o.o.-podgorica - natalizumab - rastvor za injekciju u napunjenom injekcionom špricu - 150mg

TERIFLUNOMID ZENTIVA 14mg Film tableta Montenegro - horvaadi - CInMED-Institut za ljekove i medicinska sredstva Crne Gore

teriflunomid zentiva 14mg film tableta

zentiva pharma doo - dio stranog druŠtva podgorica - teriflunomid - film tableta - 14mg

Aubagio Euroopa Liit - horvaadi - EMA (European Medicines Agency)

aubagio

sanofi winthrop industrie - teriflunomide - multipla skleroza - selektivni imunosupresivi - aubagio is indicated for the treatment of adult patients and paediatric patients aged 10 years and older with relapsing remitting multiple sclerosis (ms) (please refer to section 5. 1 for important information on the population for which efficacy has been established).

Teriflunomide Mylan Euroopa Liit - horvaadi - EMA (European Medicines Agency)

teriflunomide mylan

mylan pharmaceuticals limited - teriflunomide - multipla skleroza, Рецидивно-Ремиттирующее - imunosupresivi - teriflunomide mylan is indicated for the treatment of adult patients and paediatric patients aged 10 years and older (body weight > 40 kg) with relapsing remitting multiple sclerosis (ms) (please refer to section 5. 1 of the smpc for important information on the population for which efficacy has been established).